Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / PBYI - Health Canada OK's Knight Therapeutics Nerlynx to treat HER2-positive breast cancer

PBYI - Health Canada OK's Knight Therapeutics Nerlynx to treat HER2-positive breast cancer

Puma Biotechnology Inc
Knight Therapeutics (KHTRF) announces that Health Canada has approved Nerlynx (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens.The approval was based on results of the Phase III NALA trial.Knight has the exclusive right to commercialize Nerlynx in Canada under the terms of a license agreement entered into with Puma Biotechnology (PBYI).PBYI shares up 2.5% premarket at $9.04.

For further details see:

Health Canada OK's Knight Therapeutics Nerlynx to treat HER2-positive breast cancer
Stock Information
Company Name: Puma Biotechnology Inc
Stock Symbol: PBYI
Market: NASDAQ
Website: pumabiotechnology.com
Menu
PBYI PBYI Quote PBYI Short PBYI News PBYI Articles PBYI Message Board
Get PBYI Alerts

News, Short Squeeze, Breakout and More Instantly...